First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
Status:
Unknown status
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
A single arm, open label, phase IV trial to evaluate safety and efficacy of icotinib as
first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC
and mutated EGFR.